I specialize in the care of patients with Hodgkin’s disease (HD) and non-Hodgkin lymphoma (NHL). I am a member of the Lymphoma Service in the Division of Hematologic Oncology, and I am board certified in internal medicine and medical oncology. My clinical research interests have focused on developing a treatment program for older patients with lymphoma and designing new strategies for treating HD and NHL through clinical research.
As part of a multidisciplinary team which cares for patients age 65 and older, I have worked to develop new treatment strategies for older patients with lymphoma. We have developed new screening tools to identify patients at potentially increased risk for treatment side effects and have developed clinical trials specifically aimed at addressing the needs of the older patient population. We have as our shared goal the development of effective risk-adapted therapies to minimize the side effects of treatments and maximize their effectiveness.
As a clinical researcher, I am exploring novel biologic and immunotherapeutic agents for the treatment of HD and NHL. My prior work focused on vaccine approaches for NHL and the use of radioimmunotherapy, with ongoing efforts exploring novel antibody therapies and antibody-drug combinations.
- Clinical Expertise: Diffuse, Large B Cell Lymphoma in the Elderly; Radio-immunotherapy; Non- Hodgkin Lymphoma; Hodgkin's Disease; Mantle Cell Lymphoma
- Languages Spoken: English
- Education: MD, SUNY Downstate School of Medicine
- Residencies: NYU Medical Center
- Fellowships: Memorial Sloan Kettering Cancer Center
- Board Certifications: Internal Medicine; Medical Oncology
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Led by Paul A. Hamlin
- A Comprehensive Assessment to Predict Side Effects from Chemotherapy and an Evaluation of Pre-Phase Chemotherapy in Older Patients with Non-Hodgkin Lymphoma
- A Phase I Study of MT-3724 for the Treatment of Relapsed B-cell Non-Hodgkin Lymphoma
- A Phase I Study of PRT062070 in Patients with Persistent or Recurrent Chronic Lymphocytic Leukemia, Small Cell Lymphocytic Leukemia, or B-Cell Non-Hodgkin Lymphoma
- A Phase II Study of Brentuximab (SGN-35) Given Before and After Adriamycin, Vinblastine, and Dacarbazine Therapy in Older Adults with Untreated Hodgkin Lymphoma
- Ofatumumab with or without Bendamustine for Patients with Mantle Cell Lymphoma Who Cannot Have an Autologous Stem Cell Transplant